Madrigal Pharmaceuticals, Inc. (MDGL)
Data as of Nov 3, 12:52 PM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
MDGL key stats
MDGL GlowScore: Active
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
What's moving MDGL today
Updated November 3, 2026As of November 3, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) stock fell to $421.48, down 2.25% (-$9.69) versus the previous close. On the day, shares have traded between $410.44 and $482.73. That puts MDGL near the bottom of its 52-week range of $405.00 to $615.00. Madrigal Pharmaceuticals, Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $9.94 billion, with about 749.1K shares changing hands.
Latest MDGL news
- What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Callmarketbeat.com· Nov 3, 12:14 PM ET
- How Did Madrigal Pharmaceuticals Turn a $114 Million Loss Into a Q3 Profit as Rezdiffra Sales Surpassed $1 Billion?investorshub.advfn.com· Nov 3, 11:05 AM ET
- Madrigal (MDGL) Q3 Earnings and Revenues Beat EstimatesYahoo Finance· Nov 3, 7:15 AM ET
- Madrigal: Q3 Earnings SnapshotYahoo Finance· Nov 3, 7:09 AM ETAP
- Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate UpdatesYahoo Finance· Nov 3, 7:00 AM ET
- Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?Yahoo Finance· Oct 28, 9:13 AM ETIVA
- Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forYahoo Finance· Oct 28, 9:00 AM ETUTHR
- Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowYahoo Finance· Oct 27, 9:00 AM ET
Source: Yahoo Finance RSS · Updated November 3, 2026
Want MDGL headlines, alerts and AI research in one place? Create a free account →
MDGL buzz on Stocktwits
6,954 watchers$MDGL this is insane…
@leonbnu· Nov 3, 12:49 PM ET
$MDGL yes it’s fully manipulated idiots
@Wallst45· Nov 3, 12:48 PM ET· Bullish
$MDGL now the right time for buyout
@Wallst45· Nov 3, 12:47 PM ET· Bullish
$MDGL nothing is wrong with earnings. Market is manipulated as float is small
@Wallst45· Nov 3, 12:47 PM ET· Bullish
@flabb nice timing imo on $MDGL. pullbacks on a name finally printing profit feel like entries to me, not exits
@BiotechSwings· Nov 3, 12:26 PM ET
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
MDGL Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on MDGL
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.